Last reviewed · How we verify
Methylphenidate Pill
At a glance
| Generic name | Methylphenidate Pill |
|---|---|
| Also known as | Concerta, Ritalin |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (PHASE2)
- Methylphenidate and Response to Alcohol Cues Pilot Study (EARLY_PHASE1)
- Methylphenidate and Response to Alcohol Cues (PHASE2)
- Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints (PHASE4)
- Targeting Drug Memories With Methylphenidate (EARLY_PHASE1)
- Methylphenidate for Ptsd and Stroke Veterans (PHASE1, PHASE2)
- The Role of the Brain in Mental and Physical Fatigue (PHASE3)
- Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylphenidate Pill CI brief — competitive landscape report
- Methylphenidate Pill updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI